A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency

Inclusion Criteria: 1. Investigator-determined diagnosis of GHD prior to the historical initiation of daily rhGH trerapy 2. Participant must be 6 months to 17 years old 3. Tanner stage \<5 at Visit 1 4. Open epiphyses 5. Normal fundoscopy at Screening 6. Written, signed, informed consent of the participant's parent(s)/LAR(s) and written assent of the participant Exclusion Criteria: 1. History or presence of malignant disease 2. Children with diabetes mellitus 3. Major medical conditions and/or presence of contraindications to GH treatment 4. Pregnancy 5. Participation in any other study of an investigational agent within three months prior to Visit 1 6. Prior exposure to investigational drug or any other long-acting growth hormone 7. Any other reason per investigator's discretion